3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Renal Cell
24
Kidney Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
von Hippel-Lindau Disease
2
Neoplasm Metastasis
2
Recurrence
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Neuroectodermal Tumors, Primitive
1
Metastatic Castration-Resistant Prostate Cancer
1
Hemangioblastoma
1
Glioblastoma
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma
1
Interventions
Thalidomide
2
omburtamab I-131
1
entinostat
1
carboxyamido-triazole
1
belzutifan
1
Radiotherapy, Image-Guided
1
Paclitaxel
1
Nivolumab
1
Genistein
1
Fentanyl
1
Erlotinib Hydrochloride
1
Docetaxel
1
Cyclophosphamide
1
CLR1404
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive
×
belzutifan
×
Genitourinary
×
Clear all
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled